Summary of Precipio (PRPO) Q1 2026 Earnings Call

1Key Financial Results and Metrics

Total Revenue: $6.71 million, flat quarter-over-quarter and up over 30% year-over-year.

Pathology Revenue: Increased to over $6 million from $5.9 million in the previous quarter, up 36% from $4.4 million in Q1 2025.

Product Revenue: Decreased by $80,000 to $660,000 due to a shift in customer order timing.

Adjusted EBITDA: Negative $200,000, a significant decline from positive $960,000 in Q4 2025, primarily due to reimbursement changes and increased operational costs.

Gross Margin: 40%, down from 47% in Q4, impacted by revenue timing and reimbursement changes.

Cash Flow: Total cash flow was negative approximately $40,000, but cash flow from operations remained positive at approximately $60,000.

2Strategic Updates and Business Highlights

Precipio is focused on advancing cancer diagnostics through its clinical laboratory, which allows for rapid validation and commercialization of products.

The company has invested in a dedicated commercial team aimed at accelerating product adoption and building distributor relationships, resulting in the identification of 10 new qualified customer opportunities and adding approximately $3 million in annualized revenue potential to the pipeline.

The current commercial pipeline represents approximately $10 million in annualized revenue potential, although this does not guarantee immediate revenue.

3Forward Guidance and Outlook

The company expects continued expansion of the commercial pipeline and increased revenue conversion during the second half of 2026.

Margins are anticipated to improve as recent investments in the commercial team begin to yield results and production scales up.

Overall operational performance is expected to strengthen as the year progresses, despite potential fluctuations due to reimbursement dynamics and shipment timing.

4Bad News, Challenges, or Points of Concern

The company faced an 8% reduction in reimbursement rates for a frequently used test, leading to a $0.5 million revenue write-down and negatively impacting net income and gross margins.

Revenue predictability remains a challenge, particularly in the pathology services division, which is subject to customer transitions and external reimbursement changes.

The onboarding process for new customers can be lengthy and unpredictable, affecting revenue recognition and growth timelines.

5Notable Q&A Insights

The company has significant laboratory capacity for growth without major capital expenditures, with an annualized capacity of $45 million to $50 million.

There are no immediate plans for opening new facilities, as logistics are efficient with current operations.

Concerns about insurance reimbursement were addressed, with management expressing confidence in the stability of established CPT codes used for their tests, despite occasional rate fluctuations.

The impact of the new commercial team was noted as positive, with early results indicating a strong potential for pipeline growth, although the timeline for converting this into revenue remains uncertain.